Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05256381 · OUTCOME

Progression-free Survival According to Prostate Cancer Clinical Trials Working Group 3 Modified RECIST 1.1

A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors · Source last updated 2025-11-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Day 1 up to approximately 2 years and 2 months

Groups in this outcome

Metastatic Castration-resistant Prostate Cancer

Treatment-refractory metastatic castration-resistant prostate cancer after recurrence or failure of docetaxel and prior treatment with abiraterone, enzalutamide, or any other androgen receptor-targeted agent

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Metastatic Castration-resistant Prostate Cancer40

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Metastatic Castration-resistant Prostate Cancer2.6Not reported1.46.4Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1.4
        upper Limit
        6.4
        value
        2.6
denoms
  1. counts
    1. group Id
      OG000
      value
      40
    units
    Participants
dispersion Type
95% Confidence Interval
groups
  1. description
    Treatment-refractory metastatic castration-resistant prostate cancer after recurrence or failure of docetaxel and prior treatment with abiraterone, enzalutamide, or any other androgen receptor-targeted agent
    id
    OG000
    title
    Metastatic Castration-resistant Prostate Cancer
param Type
MEDIAN
reporting Status
POSTED
time Frame
Day 1 up to approximately 2 years and 2 months
title
Progression-free Survival According to Prostate Cancer Clinical Trials Working Group 3 Modified RECIST 1.1
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice